|
Sickness fund perspective
|
Societal perspective
|
---|
|
Marfan
|
Control
|
ATTa
| |
AI SEb
|
Marfan
|
Control
|
ATTa
| |
AI SEb
|
---|
Direct medical costs
|
4024
|
1695
|
2330
|
***
|
273
|
4105
|
1739
|
2366
|
***
|
278
|
Outpatient treatment
|
780
|
512
|
268
|
***
|
35
|
800
|
531
|
269
|
***
|
35
|
Pharmaceuticals
|
385
|
241
|
145
|
**
|
46
|
349
|
222
|
127
|
**
|
39
|
Care by non-physicians
|
1315
|
472
|
843
|
***
|
163
|
1353
|
501
|
851
|
***
|
165
|
Devices and medical appliances
|
142
|
76
|
66
|
***
|
18
|
122
|
65
|
57
|
***
|
15
|
Inpatient treatment
|
1337
|
379
|
958
|
***
|
164
|
1413
|
403
|
1010
|
***
|
173
|
Rehabilitation
|
66
|
14
|
52
|
***
|
15
|
67
|
14
|
53
|
***
|
16
|
Medical services
|
<1
|
1
|
−1
| |
5
|
<1
|
1
|
−1
| |
2
|
Direct non-medical costs
|
392
|
226
|
167
|
***
|
36
|
7431
|
1556
|
5875
|
***
|
116
|
Administration
|
192
|
192
|
0
| |
0
|
192
|
192
|
0
| |
0
|
Sick leave compensation
|
161
|
18
|
143
|
***
|
34
|
n/a
|
n/a
|
n/a
| |
n/a
|
Travel expenses
|
39
|
15
|
24
|
***
|
7
|
39
|
15
|
24
|
**
|
9
|
Other non-medical services
|
<1
|
<1
|
<1
| |
<1
|
<1
|
<1
|
<1
| |
<1
|
Informal family care
|
n/a
|
n/a
|
n/a
| |
n/a
|
7200
|
1349
|
5851
|
***
|
116
|
Indirect costs
|
n/a
|
n/a
|
n/a
| |
n/a
|
10,329
|
2842
|
7487
|
***
|
718
|
Total costs
|
4416
|
1920
|
2496
|
***
|
286
|
21,865
|
6137
|
15,728
|
***
|
824.4
|
Indicators for healthcare utilisation
| | | | | | | | | | |
Sick leave days
|
9.23
|
5.02
|
4.21
|
***
|
1.11
| | | | | |
Physician contacts
|
10.11
|
7.28
|
2.83
|
***
|
0.26
| | | | | |
Average length of stay
|
3.06
|
1.21
|
1.85
|
***
|
0.52
| | | | | |
Inpatient stays
|
0.39
|
0.18
|
0.21
|
***
|
0.04
| | | | | |
Prescriptions
|
8.70
|
6.52
|
2.18
|
***
|
0.49
| | | | | |
Average prescription cost
|
27.58
|
23.04
|
4.55
| |
3.61
| | | | | |
MRT/CT imaging
|
0.37
|
0.11
|
0.26
|
***
|
0.05
| | | | | |
- aaverage treatment effect for the treated represents excess resource utilisation attributable to Marfan.
- bAbadie–Imbens standard errors take the uncertainty of the matching process into consideration [57].
- **< 0.01 ***< 0.001.